The shares of an Indian pharmaceutical company engaged in the operation and management of Pharmaceutical Products have surged by 10 percent from the previous closing price. The company’s financial results show robust Revenue growth of 37 percent Y-O-Y, and the Net profits are up by 185 percent
The shares of Kilitch Drugs (India) Ltd, with a market capitalization of Rs. 760.37 crores on Tuesday. Its shares are trading at a CMP of Rs 472.80, against the previous closing price of Rs 438.60. The stock had surged 10 percent intraday to the high of Rs 486.00.
What Happened
Kilitch Drugs (India) Ltd, a company involved in the operation and management of Pharmaceutical Products, announced its results for the Financial year ‘25. Its Revenue grew by 37 percent YoY from Rs 44.8 Crores in Q4FY24 to Rs 61.2 Crores in Q4FY25, and it has increased by close to 8.8 percent QoQ from Rs 56.2 Crores in Q3FY25 to Rs 61.2 Crores in Q4FY25.
Its Net Profit grew by 185 percent YoY from Rs. 3.68 Crores in Q4FY24 to Rs. 10.2 Crores in Q4FY25. The Net profits have grown by 81.81 percent QoQ from Rs. 5.61 Crores in Q3FY25 to Rs. 10.2 Crores in Q4FY25.
The company’s Earnings Before Interest, Depreciation, and Taxes (EBIDT) has also grown by 106 percent YOY from Rs 7.08 crores in Q4FY24 to Rs 14.6 crores in Q4FY25. Its EPS has also grown by 190 percent YOY from Rs. 2.23 in Q4FY24 to Rs. 6.47 in Q4FY25.
About the company
Kilitch Drugs (India) Limited was incorporated in 1992. The Company is a pharmaceutical company engaged in the development, manufacturing, and marketing of quality finished dosages. The Company is one of the most reliable manufacturers of injectables in India and one of the largest manufacturers of cephalosporins in Africa, having its manufacturing unit located in India and Ethiopia. Its services range from manufacturing to marketing a host of formulations in all dosage forms, i.e., solid, liquid, and parenteral forms, of creating safe pharmaceutical solutions.
Written By Likesh Babu S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
